Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?
- PMID: 26895746
- DOI: 10.1136/annrheumdis-2016-209300
Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?
Keywords: B cells; DMARDs (biologic); Sjøgren's Syndrome.
Comment in
-
In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI.Ann Rheum Dis. 2016 Jun;75(6):e34. doi: 10.1136/annrheumdis-2016-209317. Epub 2016 Mar 9. Ann Rheum Dis. 2016. PMID: 26961295 No abstract available.
Comment on
-
Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.Ann Rheum Dis. 2016 Nov;75(11):1933-1938. doi: 10.1136/annrheumdis-2015-208304. Epub 2016 Jan 12. Ann Rheum Dis. 2016. PMID: 26757748 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
